COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals
Vivek P. Chavda, Lalitkumar K. Vora, Disha R. Vihol
Abstract
Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19Ⓡ vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.
Topics & Concepts
VirologyVaccinationVirusTransmission (telecommunications)Immune systemCoronavirus disease 2019 (COVID-19)Recombinant DNABiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Vaccine efficacyMedicineImmunologyDiseaseComputer scienceInfectious disease (medical specialty)GenePathologyTelecommunicationsBiochemistrySARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies